Last reviewed · How we verify
palliative care group first-line scheme
A palliative care regimen combining traditional Chinese medicine and supportive care approaches to manage symptoms and improve quality of life in advanced disease.
A palliative care regimen combining traditional Chinese medicine and supportive care approaches to manage symptoms and improve quality of life in advanced disease. Used for Palliative symptom management in advanced cancer, Quality of life improvement in terminal illness.
At a glance
| Generic name | palliative care group first-line scheme |
|---|---|
| Sponsor | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
| Modality | Small molecule |
| Therapeutic area | Palliative Care / Oncology Support |
| Phase | FDA-approved |
Mechanism of action
This is a first-line palliative care scheme rather than a single-entity drug, designed to address pain, symptom burden, and functional decline in patients with advanced or terminal illness. It likely integrates Chinese herbal medicine formulations with conventional supportive care, focusing on symptom management and comfort rather than curative intent.
Approved indications
- Palliative symptom management in advanced cancer
- Quality of life improvement in terminal illness
Common side effects
Key clinical trials
- Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: